ances, he now reacts toward these with emotional detachment. Usually, tension and depression give way to a state of relative tranquility.
First employed for its tuberculostatic and tuberculocidal properties alone, iproniazid administration was found to confer many other important benefits, of which at least two -relief of pain and the healing of mesodermal tissue-bear directly on the problem of pain prophylaxis in cardiovascular disease. Under iproniazid therapy the influence toward healing of mesodermal tissue has proved out of proportion to any influence of the chemical on the tuberele organism alone. Relief from pain has been such that in one patient with an extensive destructive neoplasm of the right pelvis, iproniazid administration has permitted increased hip movement and the discontinuance of 200 mg. of Demerol every 3 hours. 2 Because of its potent appetite-stimulating effects, iproniazid has been employed with profit in the treatment of poor appetite due to hepatitis, cirrhosis, anorexia nervosa, poor iiutritional state due to duodenal ulcer, ulcerative colitis, geriatric wasting, and chronic its beneficial effects on mood and activity, iproniazid administration has been found to increase physician-patient rapport: the patient both seeks and is additionally receptive to support and reassurance.
All these elements-pain relief, healing of mesodermal tissues, appetite stimulation, closer physician-patient rapport, and elevation of mood-are most important in the therapy of the patient with angina pectoris, who not only is limited in his capacity for effort but usually is very fearful of the outcome of his illness.
Biochemical and Physiologic Results of MAO-Inhibition
The effect of MAO-inhibitors on serotonin metabolism has received particularly close attention, inasmuch as iproniazid adininistration increases brain serotonin levels to 2 or 3 times normal.5 Following a single dose of iproniazid, the highest brain serotonin level is attained within 3 to 5 hours and tapers off within a few hours :6 repeated doses administered over several days do not raise brain serotonin levels above the concentration produced by a single dose.7 Iproniazid has been shown to have little effect on the peripheral metabolism of serotonin, with no increase of serotonin determinable in blood, stomach, or intestines, despite the marked increase in brain serotonin. 6 Apparently, iproniazid does not exert a significant effect on the coneentrations of epinephrine or norepinephrine ;8 the primary effect of iproniazid seems to be not on the level of the amines themselves but on their metabolites. As measured by the metabolism of methyl-labeled epiuephrine, the biochemical effects of iproniazid in man persist for 2 or 3 weeks after cessation of iproniazid therapy. MIaster and Donoso,37 too, found that maniy patients could be imaintained on small doses.
Isocarboxazid
This preparation purportedly is 7 times as effective as iproniazid in inhibiting MAO in vitro and 8 times as potent in potentiating the central nervous system action of 5-hydroxytryptophane in mice. Its action is far more potent in the brain (33 times that of iproniazid) than in the heart (8 times that of iproniazid) .50 This increase in potency makes possible an average clinical dose of one quarter to one fifth that of iproniazid, and may be a factor in the reduction of frequency and severity of side effects reported with the newer preparation. We have employed 2 methods in administering isocarboxazid: in our younger and less seriously ill patients, we have started with the maximum dosage in order to reach full effectiveness within the shortest possible period; and we later have reduced dosage to the smallest amount that served to maintaini the antianginal effect. In older and more seriously ill patients, we have administered smaller amounts and in divided doses. Although this might delay the energizing and anitianginal effects of the drug, a wider margin of safety exists.
Over 70 per cent of our patients report appreciable benefit from isocarboxazid. We rarely have administered above 30 mg. per day: the majority of our patients have achieved maximum benefit with 15 to 30 mg.
per day. This preparation has proved as effective as and frequently more effective than iproniazid, and sometimes is faster in onset of action.
Beta-phenylisopropylhydrazine
Eight times as potent in inhibiting MAO in vitro as iproniazid, beta-phenylisopropylhydrazine is 40 times as effective in vivo in inhibiting heart MAO and 43 times as effective as iproniazid in inhibiting brain MAO. 50 We have found isocarboxazid and beta-phenylisopropylhydrazine about equally effective in the prophylaxis of angina pectoris. Our eustomary procedure is to provide patients initially with 9 mg. of the preparation daily, in divided doses. In patients who receive complete relief of pain with this dosage, it later is reduced to 3 mg. twice daily. A reversible red-green color defect has been reported in a few patients on extended therapy with large doses of this agent.
Beta-phenylisopropylhydrazine has been used alone and in combination with chlorothiazide as an antihypertensive agent. 
